New research suggests that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Findings released in a prominent health publication shows that while overweight individuals frequently drop about a fifth of their body weight while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"Individuals using such treatments must be aware of the danger of fast rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment weight within about one and a half years.
Weighing Treatments
The study, which looked at dozens of studies involving over 9,000 of participants, compared the results of the injectable medications with conventional dieting.
Scientists point out that people who shed pounds through diet and exercise usually have a slower weight regain—around 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Nutrition scientists believe the mode of action of the jabs is key to understanding the accelerated weight return.
The injections copy a natural hormone called GLP-1, which controls appetite.
"Long-term administration of GLP-1 levels far above than the body's typical production may cause the body to produce less of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication means hunger is no longer kept in check, making binge eating much more probable."
A Lifelong Issue?
The NHS recommend the injections for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians say that, given the significant potential of relapse, the therapy is often long-term.
This view is supported by pharmaceutical companies, who note that the results "highlight the persistent character of obesity," comparing it to managing diseases like diabetes.
Patient Testimonies
People who have discontinued the medication report a sudden return of cravings.
"It was like a switch activating and I was suddenly starving," described a patient.
This challenge is compounded if users have not developed lasting lifestyle or habit modifications during therapy.
Significant Use
Survey data indicate that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Use is higher among females compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, researchers stress that while these medications are potent agents for weight loss, they are not a magic fix and long-term success hinges on integrated lifestyle support.
